FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:627-629 August 10, 2006 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Berman, E. PubMed Citation

To the Editor: Berman and colleagues (May 11 issue)¹ report their findings regarding the development of hypophosphatemia and associated changes in bone and mineral metabolism in patients with either chronic myelogenous leukemia or gastrointestinal stromal tumors who are taking imatinib. We have reviewed the global database of clinical trials sponsored by Novartis, as well as spontaneous post-marketing reports that cover approximately 200,000 patient-years of treatment with imatinib (unpublished data). There was a low incidence of reported hypophosphatemia or potential related events, although we recognize that the observations may be underreported.

Serum phosphate levels were routinely measured in two clinical trials . . . [Full Text of this Article]

This article has been cited by other articles:

• de Oliveira, R. A., Marques, I. D. B., Seguro, A. C., Andrade, L. (2008). Electrolyte disturbances and acute kidney injury induced by imatinib therapy. NDT Plus 0: sfn188v1-sfn188 [Abstract] [Full Text]  
• Jonsson, S., Olsson, B., Ohlsson, C., Lorentzon, M., Mellstrom, D., Wadenvik, H. (2008). Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. haematol 93: 1101-1103 [Full Text]